TABLE 1.
MIC distributions for Pseudomonas aeruginosa and Pseudomonas species other than P. aeruginosa from 2013 to 2022a
| Antimicrobial agent | Dilution (µg/mL) | Total | MIC50 | MIC90 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | > | ||||
| Tobramycin (PA) | 561 | 2,228 | 10,987 | 5,298 | 1,064 | 342 | 223 | 1,849 | 22,552 | 0.5 | 4 | ||||||
| Tobramycin (POPA) | 57 | 217 | 117* | 16 | 7 | 3 | 6 | 15 | 438 | 0.25 | 1 | ||||||
| Pip-tazo (PA) | 733 | 338 | 1,325 | 9,844 | 3,203 | 2,161 | 1,355 | 1,039 | 2,545 | 22,543 | 4 | >64 | |||||
| Pip-tazo (POPA) | 20 | 38 | 38 | 95 | 132 | 98 | 22 | 11* | 15 | 469 | 8 | 32 | |||||
| Imipenem (PA) | 245 | 683 | 5,736 | 8,841 | 1,581 | 877 | 1,717 | 2,863 | 22,543 | 1 | >8 | ||||||
| Imipenem (POPA) | 36 | 102 | 177 | 59 | 25* | 24 | 18 | 27 | 468 | 0.5 | 4 | ||||||
| Meropenem (PA) | 125 | 262 | 1,287 | 2,432 | 4,716 | 4,224 | 2,844 | 1,572 | 1,299 | 1,224 | 1,242 | 667 | 645 | 22,539 | 0.5 | 16 | |
| Meropenem (POPA) | 57 | 19 | 18 | 19 | 50 | 135 | 100 | 38 | 31 | 467 | 2 | 8 | |||||
| Cefepime (PA) | 59 | 145 | 393 | 3,573 | 7,978 | 3,231 | 3,419 | 2,183 | 1,557 | 22,538 | 2 | 16 | |||||
| Cefepime (POPA) | 91 | 54 | 151 | 111 | 24 | 12* | 25 | 468 | 2 | 8 | |||||||
| Ceftazidime (PA) | 0 | 1 | 3 | 13 | 84 | 386 | 4,117 | 9,383 | 2,963 | 1,501 | 1,000 | 1,283 | 1,805 | 22,539 | 2 | 32 | |
| Ceftazidime (POPA) | 48 | 25 | 66 | 155 | 92 | 19 | 11* | 21 | 437 | 2 | 8 | ||||||
| Aztreonam (PA) | 3 | 10 | 82 | 381 | 446 | 299 | 906 | 7,374 | 6,250 | 2,581 | 4,202 | 22,534 | 8 | >16 | |||
| Aztreonam (POPA) | 5 | 11 | 10 | 9 | 14 | 14 | 42 | 120 | 212 | 437 | 16 | >16 | |||||
| Ciprofloxacin (PA) | 562 | 2,160 | 9,026 | 2,890 | 2,146 | 1,256 | 971 | 747 | 2,762 | 22,520 | 0.12 | >4 | |||||
| Ciprofloxacin (POPA) | 76 | 75 | 150 | 78 | 23* | 13 | 5 | 12 | 36 | 468 | 0.12 | 4 | |||||
| Levofloxacin (PA) | 131 | 193 | 437 | 2,363 | 9,328 | 2,591 | 2,080 | 1,482 | 3,910 | 22,515 | 0.5 | >4 | |||||
| Levofloxacin (POPA) | 100 | 51 | 143 | 100 | 20 | 10* | 43 | 467 | 0.5 | 4 | |||||||
| Amikacin (PA) | 113 | 443 | 742 | 4,821 | 9,977 | 3,690 | 1,149 | 501 | 22,549 | 4 | 16 | ||||||
| Amikacin (POPA) | 27 | 98 | 157 | 110 | 24* | 9 | 3 | 0 | 10 | 438 | 1 | 4 | |||||
| SXT (PA) | 808 | 618 | 3,481 | 7,851 | 9,781 | 22,539 | 4 | >4 | |||||||||
| SXT (POPA) | 87 | 35 | 56 | 72 | 218 | 468 | 4 | >4 | |||||||||
Pip-tazo: piperacillin-tazobactam; SXT: trimethoprim-sulfamethoxazole. Modal MIC is bolded, and epidemiological cutoff values (ECVs) are indicated by asterisks (*). PA, Pseudomonas aeruginosa; POPA, Pseudomonas species other than P. aeruginosa.